Guadagni F, Roselli M, Cosimelli M, Mannella E, Tedesco M, Cavaliere F, Grassi A, Abbolito M R, Greiner J W, Schlom J
Regina Elena Cancer Institute, Rome, Italy.
Cancer. 1993 Oct 1;72(7):2098-106. doi: 10.1002/1097-0142(19931001)72:7<2098::aid-cncr2820720707>3.0.co;2-g.
Serum carcinoembryonic antigen (CEA) is the most frequently chosen tumor marker in the clinical diagnosis of colorectal carcinoma and in the long-term monitoring of patients after tumor resection. In recent years, monoclonal antibody technology has identified several new markers of neoplasia, two of which, TAG-72 and CA 19-9, are found in the sera of patients with adenocarcinoma. Serum CEA, TAG-72, and CA 19-9 were evaluated in 300 patients with either malignant (n = 200) or benign (n = 100) colorectal disease.
Serum CEA, TAG-72 (CA 72-4), and CA 19-9 antigen levels were determined with a double-determinant radioimmunometric assay kit. Samples and appropriate standards were assayed in duplicate. The cutoff limits used for each assay were indicated by the manufacturer. All of the results of the CA 72-4, CEA, and CA 19-9 serum assays were separated from the clinical information until the study was completed.
Of the 200 patients with colorectal carcinoma, the percentage of patients whose serum samples were positive for CEA, TAG-72, or CA 19-9 was 43%, 43%, and 27%, respectively. The measurement of TAG-72 with CEA for patients with primary or recurrent colorectal carcinoma increased substantially (to 60%) the percentage of positive serum samples when compared with measuring each serum tumor marker alone. Moreover, the apparent advantage gained by measuring the two tumor markers was achieved with little increase in the number of false-positive results.
The findings support previous observations of complementary expression of TAG-72 and CEA and indicate that a significant advantage could be gained in the detection of primary and, perhaps, recurrent colorectal carcinoma by incorporating the measurement of serum TAG-72 with that of CEA.
血清癌胚抗原（CEA）是结直肠癌临床诊断及肿瘤切除术后患者长期监测中最常选用的肿瘤标志物。近年来，单克隆抗体技术已鉴定出几种新的肿瘤形成标志物，其中两种，即TAG-72和CA 19-9，在腺癌患者血清中被发现。对300例患有恶性（n = 200）或良性（n = 100）结直肠疾病的患者的血清CEA、TAG-72和CA 19-9进行了评估。
采用双决定簇放射免疫分析试剂盒测定血清CEA、TAG-72（CA 72-4）和CA 19-9抗原水平。样本和适当的标准品均进行双份测定。每种检测的临界值由制造商指定。在研究完成之前，CA 72-4、CEA和CA 19-9血清检测的所有结果均与临床信息分开。
在200例结直肠癌患者中，血清样本CEA、TAG-72或CA 19-9呈阳性的患者百分比分别为43%、43%和27%。与单独检测每种血清肿瘤标志物相比，对原发性或复发性结直肠癌患者联合检测TAG-72和CEA可使血清样本阳性百分比大幅增加（至60%）。此外，联合检测这两种肿瘤标志物在假阳性结果数量增加很少的情况下获得了明显优势。
这些发现支持了先前关于TAG-72和CEA互补表达的观察结果，并表明通过将血清TAG-72检测与CEA检测相结合，在原发性及可能的复发性结直肠癌检测中可获得显著优势。
